SynthesisFrontiers in immunology2021
Mucosal Immunization Against Pertussis: Lessons From the Past and Perspectives.
Synthesis in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 32 citations in OpenAlex.
- Immunological insights into why pertussis continues to be endemic.Human vaccines & immunotherapeutics · 2026Review
- Article
- From Jenner to genomics: the unfolding future of vaccinology.Frontiers in immunology · 2026Review
- Innovative adjuvant strategies for next-generation pertussis vaccines.Human vaccines & immunotherapeutics · 2025Review
- Variation in virulence between three representativemSphere · 2025Article
- In silico design and evaluation of a multiepitope vaccine against Bordetella pertussis: structural, immunological, and biological properties.Genomics & informatics · 2025Article
- Article
- Clinical and Epidemiological Characteristics of Pediatric Pertussis Cases: A Retrospective Study from Southeast Romania.Antibiotics (Basel, Switzerland) · 2025Article
- Pertussis before, during and after Covid-19.EMBO molecular medicine · 2025Review
- Review
- Mucosal IgA Antibodies are Critical for Bacterial Clearance ofPathogens & immunity · 2025Article
- Pertussis resurgence: epidemiological trends, pathogenic mechanisms, and preventive strategies.Frontiers in immunology · 2025Review
- Chicken Secondary Lymphoid Tissues-Structure and Relevance in Immunological Research.Animals : an open access journal from MDPI · 2024Review
- Resurgence of pertussis: reasons and coping strategies.World journal of pediatrics : WJP · 2024Article
- mRNA Technology and Mucosal Immunization.Vaccines · 2024Review
- IL-10 inhibition during immunization improves vaccine-induced protection against Staphylococcus aureus infection.JCI insight · 2024Article
- BECC438b TLR4 agonist supports unique immune response profiles from nasal and muscular DTaP pertussis vaccines in murine challenge models.Infection and immunity · 2024Article
- Repeated Bordetella pertussis Infections Are Required to Reprogram Acellular Pertussis Vaccine-Primed Host Responses in the Baboon Model.The Journal of infectious diseases · 2024Article
- Coping Strategies for Pertussis Resurgence.Vaccines · 2023Review
- Antigen Discovery for Next-Generation Pertussis Vaccines Using Immunoproteomics and Transposon-Directed Insertion Sequencing.The Journal of infectious diseases · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Current vaccination strategies against pertussis are sub-optimal. Optimal protection against Objectives: In this review we systematically analyzed published literature on protection conferred by mucosal immunization against pertussis. Immune responses mounted by these vaccines are summarized. Method: The PubMed Library database was searched for published studies on mucosal pertussis vaccines. Eligibility criteria included mucosal administration and the evaluation of at least one outcome related to efficacy, immunogenicity and safety. Results: While over 349 publications were identified by the search, only 63 studies met the eligibility criteria. All eligible studies are included here. Initial attempts of mucosal whole-cell vaccine administration in humans provided promising results, but were not followed up. More recently, diverse vaccination strategies have been tested, including non-replicating and replicating vaccine candidates given by three different mucosal routes: orally, nasally or rectally. Several adjuvants and particulate formulations were tested to enhance the efficacy of non-replicating vaccines administered mucosally. Most novel vaccine candidates were only tested in animal models, mainly mice. Only one novel mucosal vaccine candidate was tested in baboons and in human trials. Conclusion: Three vaccination strategies drew our attention, as they provided protective and durable immunity in the respiratory tract, including the upper respiratory tract: acellular vaccines adjuvanted with lipopeptide LP1569 and c-di-GMP, outer membrane vesicles and the live attenuated BPZE1 vaccine. Among all experimental vaccines, BPZE1 is the only one that has advanced into clinical development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.